Role of tyrosine kinases in gastrointestinal malignancies. (2018)
- Record Type:
- Book
- Title:
- Role of tyrosine kinases in gastrointestinal malignancies. (2018)
- Main Title:
- Role of tyrosine kinases in gastrointestinal malignancies
- Further Information:
- Note: Ganji Purnachandra Nagaraju, editor.
- Editors:
- Nagaraju, Ganji Purnachan
- Contents:
- Intro; Dedication; Preface; Contents; Contributors; About the Editor; 1: HGFR and FGR2: Their Roles in Progression and Metastasis of Esophageal Cancer; 1.1 Introduction/Background; 1.2 Clinical Characteristics of Esophageal Cancer; 1.3 Structures of Hepatocyte Growth Factor Receptor (HGFR) and Fibroblast Growth Factor Receptor 2 (FGR2); 1.4 Expression and Roles of HGFR and FGFR2 in EC; 1.5 Signaling Pathways Related to HGFR and FGR2 in EC; 1.5.1 Structure and Functions of HGF and c-Met Receptors; 1.5.2 HGF-c-Met Signaling Mechanisms 1.5.3 Role of MET Signaling in Physiologic and Pathologic Growth1.5.4 Structure, Functions, and Signaling of FGR2; 1.5.5 Role of FGFR2 in Esophageal Cancer; 1.6 Molecular-Targeted Therapy of the HGFR and FGFR2 in EC; 1.6.1 c-Met-Targeted Therapies, Adverse Reactions, and Relevant Clinical Trials; 1.6.2 FGFR-Targeted Therapies, Their Adverse Reactions, and Relevant Clinical Trials; 1.7 Economic/Financial Issues for Patients, Professionals, and Hospitals; 1.8 Conclusions and Future Perspectives; References; 2: Role of Src and VEGFR Tyrosine Kinases in Esophageal Cancer 2.1 Introduction2.1.1 Src and Esophageal Cancer; 2.1.2 VEGFR (Vascular Endothelial Growth Factor) and Esophageal Cancer; References; 3: The Clinical and Biological Significance of Tyrosine Kinases in Gastric Cancer; 3.1 Introduction/Background; 3.2 Characterization of Gastric Cancer with Genomic and Molecular Analyses to Stratify the Heterogeneous Disease; 3.2.1 Genomics of GastricIntro; Dedication; Preface; Contents; Contributors; About the Editor; 1: HGFR and FGR2: Their Roles in Progression and Metastasis of Esophageal Cancer; 1.1 Introduction/Background; 1.2 Clinical Characteristics of Esophageal Cancer; 1.3 Structures of Hepatocyte Growth Factor Receptor (HGFR) and Fibroblast Growth Factor Receptor 2 (FGR2); 1.4 Expression and Roles of HGFR and FGFR2 in EC; 1.5 Signaling Pathways Related to HGFR and FGR2 in EC; 1.5.1 Structure and Functions of HGF and c-Met Receptors; 1.5.2 HGF-c-Met Signaling Mechanisms 1.5.3 Role of MET Signaling in Physiologic and Pathologic Growth1.5.4 Structure, Functions, and Signaling of FGR2; 1.5.5 Role of FGFR2 in Esophageal Cancer; 1.6 Molecular-Targeted Therapy of the HGFR and FGFR2 in EC; 1.6.1 c-Met-Targeted Therapies, Adverse Reactions, and Relevant Clinical Trials; 1.6.2 FGFR-Targeted Therapies, Their Adverse Reactions, and Relevant Clinical Trials; 1.7 Economic/Financial Issues for Patients, Professionals, and Hospitals; 1.8 Conclusions and Future Perspectives; References; 2: Role of Src and VEGFR Tyrosine Kinases in Esophageal Cancer 2.1 Introduction2.1.1 Src and Esophageal Cancer; 2.1.2 VEGFR (Vascular Endothelial Growth Factor) and Esophageal Cancer; References; 3: The Clinical and Biological Significance of Tyrosine Kinases in Gastric Cancer; 3.1 Introduction/Background; 3.2 Characterization of Gastric Cancer with Genomic and Molecular Analyses to Stratify the Heterogeneous Disease; 3.2.1 Genomics of Gastric Cancer; 3.2.2 Gene Mutations in Gastric Cancer; 3.2.3 Chromosomal Instability; 3.2.4 Transcriptional Changes in Gastric Cancer; 3.2.5 Epigenetic Modifications in Gastric Cancer 3.2.6 Molecular and Genomic Stratification of Gastric Cancer3.3 Role of Tyrosine Kinases, Receptors, and Inhibitors in Gastric Cancer; 3.3.1 Receptor Tyrosine Kinases in Gastric Cancer; 3.3.2 Role of EGF Receptor/HER Tyrosine Kinase Family in Gastric Cancer; 3.3.3 Vascular Endothelial Growth Factor Receptor; 3.3.4 Fibroblast Growth Factor Receptor; 3.3.5 Platelet-Derived Growth Factor Receptor; 3.3.6 Combined VEGFR and PDGFR Tyrosine Kinase Inhibitors; 3.3.7 Hepatocyte Growth Factor Receptor Tyrosine Kinase; 3.4 Targeted Therapies and Ongoing Clinical Trials 3.4.1 Targeted Therapies for HER-2 Overexpressed Gastric Cancers3.4.2 Ongoing Trials for HER-2 Targeted Therapies; 3.4.3 Targeted Therapies for the VEGF-Positive Gastric Cancers; 3.4.4 Trials for VEGF Targeted Therapies; 3.4.5 Anti-EGFR-Targeted Therapies and Trials; 3.4.6 Targeted Therapies for Gastric Cancers with FGFR2 Amplification; 3.4.7 Clinical Trials for FGFR2-Targeted Therapies; 3.4.8 Targeted Therapies for the PI3K Pathway and Clinical Trials; 3.4.9 Targeted Therapies and Clinical Trials for MET-Amplified Gastric Tumors; 3.4.10 Immunotherapy for Gastric Cancer … (more)
- Publisher Details:
- Singapore : Springer
- Publication Date:
- 2018
- Extent:
- 1 online resource
- Subjects:
- 612.0151
Medicine
Protein-tyrosine kinase
Digestive organs -- Cancer -- Diagnosis
Digestive organs -- Cancer -- Treatment
MEDICAL / Physiology
SCIENCE / Life Sciences / Human Anatomy & Physiology
Medical -- Physiology
Science -- Life Sciences -- Biology -- Molecular Biology
Science -- Life Sciences -- Biochemistry
Medical -- Genetics
Medical -- Oncology
Physiology
Cellular biology (cytology)
Proteins
Medical genetics
Oncology
Oncology
Human physiology
Cytology
Cell receptors
Gene expression
Oncology
Electronic books - Languages:
- English
- ISBNs:
- 9789811314865
9811314861 - Related ISBNs:
- 9789811314858
9811314853 - Notes:
- Note: Includes bibliographical references.
Note: Vendor-supplied metadata. - Access Rights:
- Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
- Access Usage:
- Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library HMNTS - ELD.DS.334177
- Ingest File:
- 01_279.xml